Evidence check: CYP2D6 in the context of menopause

The question about CYP2D6 in the context of menopause is relevant because this enzyme metabolizes several drugs commonly used during this life stage, including selective serotonin reuptake inhibitors (SSRIs) for hot flashes and tamoxifen for breast cancer prevention or treatment. CYP2D6 variants can slow or accelerate drug metabolism, potentially affecting efficacy and side effects. However, the evidence for routine genetic testing in menopause is limited. Most studies are observational or pharmacokinetic; large randomized controlled trials demonstrating clinical utility are lacking. Moreover, CYP2D6 influence is confounded by liver function, co-medications, and diet. The American Society of Clinical Oncology does not recommend routine CYP2D6 testing for tamoxifen due to inconsistent data. For SSRIs, no clear guideline exists. There is no direct evidence that a specific CYP2D6 variant itself influences menopausal symptoms. Therefore, caution is warranted: a genetic test may provide hints but should not be the sole basis for decisions. The evidence is rated as unclear because the provided context contains no specific data on CYP2D6 and menopause. Always consult a physician before adjusting medications based on genetic results.